<DOC>
	<DOCNO>NCT00328627</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy alogliptin , daily ( QD ) , take combination pioglitazone adult type 2 diabetes mellitus .</brief_summary>
	<brief_title>Efficacy Safety Alogliptin Combined With Pioglitazone Treating Subjects With Type 2 Diabetes Mellitus .</brief_title>
	<detailed_description>Over past 30 year , prevalence diabetes increase dramatically throughout world due population growth , age , urbanization , increase obesity , physical inactivity . The total number people type 2 diabetes mellitus project rise 171 million 2000 366 million 2030 . The incidence type 2 diabetes mellitus United States alone expect increase approximately 17 30.3 million year 2030 . Type 2 diabetes mellitus associate number long-term microvascular macrovascular complication associate reduced quality life increase morbidity mortality . It anticipate increase incidence type 2 diabetes mellitus place ever-increasing burden family , increase national expenditure health care service , decrease worker productivity . Current pharmacologic intervention type 2 diabetes mellitus include diverse range antidiabetic medication different mechanism action include insulin insulin analogue , sulfonylurea , metformin , meglitinides , thiazolidinediones , inhibitor alpha-glucosidase , analogs glucagon-like peptide-1 synthetic analogue human amylin . Despite variety medication , many clinically important potentially life-threatening side effect , restrict use many subpopulation , concern long-term tolerability , challenge relate compliance due side effect route administration . All reason contribute difficulty patient achieve target glycosylated hemoglobin level less 7 % . SYR-322 ( alogliptin ) selective , orally available inhibitor dipeptidyl peptidase-4 enzyme . Dipeptidyl peptidase-4 enzyme think primarily responsible vivo degradation 2 peptide hormone release response nutrient ingestion , namely glucagon-like peptide-1 glucose-dependent insulinotropic peptide . Both peptide exert important effect islet beta cell stimulate glucose-dependent insulin secretion well regulate beta cell proliferation cytoprotection . Glucagon-like peptide-1 , glucose-dependent insulinotropic peptide , inhibit gastric emptying , glucagon secretion , food intake . Glucose-dependent insulinotropic peptide show enhance insulin secretion direct interaction glucose-dependent insulinotropic peptide -specific receptor islet beta cell . The glucose-lowering action glucagon-like peptide-1 , glucose-dependent insulinotropic peptide , preserve patient type 2 diabetes mellitus . Pioglitazone ( ACTOSÂ® ) thiazolidinedione develop Takeda Chemical Industries , Ltd. ( Osaka , Japan ) approve treatment type 2 diabetes mellitus . Pioglitazone selective peroxisome proliferator-activated receptor-gamma agonist decrease insulin resistance periphery liver result increased insulin-dependent glucose disposal decrease hepatic glucose output . Given complementary mechanism action alogliptin ( stimulation insulin secretion ) pioglitazone ( enhancement insulin sensitivity ) , goal study evaluate efficacy combination alogliptin pioglitazone patient inadequately control metformin . Study participation anticipate approximately 7 month .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Alogliptin</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Men woman historical diagnosis type 2 diabetes mellitus treat metformin great equal 1500 mg alone experience inadequate glycemic control . A stable dose metformin great equal 1500 mg maximum tolerate dose . No treatment antidiabetic agent metformin within 2 month prior Screening . A body mass index great equal 23 kg/m^2 less equal 45 kg/m^2 . Fasting Cpeptide great equal 0.8 ng/mL . Regular use , nonexcluded medication allow stable dose establish least 4 week prior Screening . Systolic blood pressure less equal 160 mmHg diastolic pressure less equal 100 mmHg . Hemoglobin great equal 12 g/dL men great equal 10 g/dL woman . Alanine aminotransferase less equal 2.5 time upper limit normal . Serum creatinine le 1.5 mg/dL men le 1.4 mg/dL woman . Thyroidstimulating hormone level less equal upper limit normal range subject clinically euthyroid . Females childbearing potential sexually active must agree use adequate contraception , neither pregnant lactating Screening throughout duration study . Able willing monitor blood glucose concentration home glucose monitor . No major illness debility investigator 's opinion prohibit patient completing study . Urine albumin/creatinine ratio great 113 mg/mmol Screening . A history cancer , squamous cell basal cell carcinoma skin , full remission least 5 year prior Screening . A history laser treatment proliferative diabetic retinopathy within 6 month prior Screening . A history treat diabetic gastroparesis . New York Heart Association Class III IV heart failure regardless therapy . History coronary angioplasty , coronary stent placement , coronary bypass surgery , myocardial infarction within 6 month prior Screening . History hemoglobinopathy . History infection hepatitis B , hepatitis C human immunodeficiency virus . History psychiatric disorder could affect patient 's ability participate study . History angioedema association use angiotensinconverting enzyme inhibitor angiotensinII receptor inhibitor . A history alcohol substance abuse within 2 year prior Screening . Receipt investigational drug within 30 day prior Screening history receipt investigational antidiabetic drug within 3 month prior Screening . Previous participation investigational study alogliptin . Hypersensitive pioglitazone , alogliptin , excipients .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Diabetes Mellitus , Non Insulin Dependent</keyword>
	<keyword>Glucose Intolerance</keyword>
	<keyword>Hyperglycemia</keyword>
</DOC>